Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals Free Cash Flow : -177.46M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -177.46M |
| June 30, 2026 | -220.87M |
| March 31, 2026 | -278.35M |
| December 31, 2025 | -323.17M |
| September 30, 2025 | -311.01M |
| June 30, 2025 | -302.67M |
| March 31, 2025 | -286.52M |
| December 31, 2024 | -274.90M |
| September 30, 2024 | -258.86M |
| June 30, 2024 | -241.20M |
| March 31, 2024 | -204.92M |
| December 31, 2023 | -160.60M |
| September 30, 2023 | -142.15M |
| June 30, 2023 | -126.04M |
| March 31, 2023 | -130.97M |
| December 31, 2022 | -133.68M |
| September 30, 2022 | -10.20M |
| June 30, 2022 | -6.601M |
| March 31, 2022 | 9.66M |
| December 31, 2021 | 29.00M |
| September 30, 2021 | -87.21M |
| June 30, 2021 | -80.56M |
| Date | Value |
|---|---|
| March 31, 2021 | -77.92M |
| December 31, 2020 | -71.26M |
| September 30, 2020 | -68.36M |
| June 30, 2020 | -58.59M |
| March 31, 2020 | -49.71M |
| December 31, 2019 | -50.61M |
| September 30, 2019 | -52.94M |
| June 30, 2019 | -62.88M |
| March 31, 2019 | -65.51M |
| December 31, 2018 | -68.72M |
| September 30, 2018 | -66.42M |
| June 30, 2018 | -58.18M |
| March 31, 2018 | -54.83M |
| December 31, 2017 | -47.46M |
| September 30, 2017 | -45.11M |
| June 30, 2017 | -46.39M |
| March 31, 2017 | -41.55M |
| December 31, 2016 | -35.42M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| September 30, 2014 | -13.70M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| ACADIA Pharmaceuticals, Inc. | -- |
| Emergent BioSolutions, Inc. | 188.40M |
| Incyte Corp. | 679.87M |
| Vertex Pharmaceuticals, Inc. | 3.202B |
| Travere Therapeutics, Inc. | 85.72M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -27.25M |
| Cash from Investing (Quarterly) | -176.47M |
| Cash from Financing (Quarterly) | 3.189M |
| Free Cash Flow Per Share (Quarterly) | -0.3035 |
| Free Cash Flow to Equity (Quarterly) | -27.29M |
| Free Cash Flow to Firm (Quarterly) | -14.28M |
| Free Cash Flow Yield | -20.99% |